S100A8 and familial pancreatic carcinoma: These observations complement previous work depicting MDSCs as mediators of resistance to antiangiogenic therapies through their ability to secrete vascular-remodeling factors, such as MMP9 and S100A8/A9, and corroborate the production of CCL9 as a mediator of immune resistance in pancreatic cancer (47–51).